Ladenburg lowered the firm’s price target on Checkpoint Therapeutics to $47 from $65 and keeps a Buy rating on the shares. The analyst says updated cosibelimab metastatic and locally advanced cutaneous squamous cell carcinoma data show substantial increases in complete response rates with longer treatment. However, the firm dropped the price target based on the incorporation of the dilution associated with the company’s recent financings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics reports Q2 EPS ($1.05), consensus (78c)
- Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- MidCoast Council deploys Check Point Infinity
- Checkpoint to sell 3.2M shares at $3.09 in registered direct offering
- Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market